Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GUSB | P08236 | 2/20 | 0.40 |
| ▸ | EBP | Q15125 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | GNAI3 | P08754 | 3/20 | 0.37 |
| ▸ | GNAO1 | P09471 | 3/20 | 0.37 |
| ▸ | GNAI1 | P63096 | 3/20 | 0.37 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.36 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.36 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.36 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.36 |
| ▸ | FDPS | P14324 | 4/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | GBA1 | P04062 | 1/20 | 0.34 |
| ▸ | BCHE | P06276 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20892894 | 1.00 | GUSB (0.40) | GUSBEBPSIGMAR1GNAI3GNAO1 | |
| SCHEMBL21160999 | 0.86 | FDPS (0.37) | GUSBEBPSIGMAR1FDPS | |
| SCHEMBL25834503 | 0.86 | FDPS (0.37) | GUSBEBPSIGMAR1FDPS | |
| SCHEMBL21161001 | 0.86 | FDPS (0.37) | GUSBEBPSIGMAR1FDPS | |
| SCHEMBL23695714 | 0.85 | S1PR1 (0.43) | GUSBEBPSIGMAR1GNAI3GNAO1 | |
| SCHEMBL24764520 | 0.85 | S1PR1 (0.43) | GUSBEBPSIGMAR1GNAI3GNAO1 | |
| SCHEMBL21106761 | 0.85 | S1PR1 (0.43) | GUSBEBPSIGMAR1GNAI3GNAO1 | |
| SCHEMBL23695711 | 0.85 | GUSB (0.39) | GUSBEBPSIGMAR1GNAI3GNAO1 | |
| SCHEMBL25836038 | 0.84 | FDPS (0.35) | FDPS | |
| SCHEMBL25653853 | 0.79 | S1PR1 (0.44) | GUSBEBPSIGMAR1GNAI3GNAO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11318205-B1 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2022-05-03 | — | — | US | disclosed |
| US-11117889-B1 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2021-09-14 | — | — | US | disclosed |
| US-10874743-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2020-12-29 | — | — | US | disclosed |
| US-20190192668-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2019-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10874743-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | GUSB 1746/4885EBP 3184/4885SIGMAR1 3199/4885 |
| US-11117889-B1 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | GUSB 1746/4885EBP 3184/4885SIGMAR1 3199/4885 |
| US-20190192668-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | GUSB 1746/4885EBP 3184/4885SIGMAR1 3199/4885 |
| US-11318205-B1 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | GUSB 1746/4885EBP 3184/4885SIGMAR1 3199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.